Oncophage Effect In Subgroup Supports Continued Development, Firm Says
Executive Summary
Antigenics is seeing salvation for its Oncophage cancer vaccine based on signs of a clinically significant improvement in a subgroup of patients with a better prognosis in its Phase III renal cell carcinoma trial